With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

On March 13, 2025, the Federal Circuit decided in Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254) how ...

Pharmaceutical company Novartis is laying off more than 400 employees at its East Hanover facility as part of a restructuring ...

Somehow Washington regards the industry, which has saved and improved tens of millions of lives, as a villain.

BioCryst Pharmaceuticals sues Hetero with claims of Orladeyo patent infringement. Orladeyo generated $437.7 million in revenue for BioCryst last year. BioCryst seeks court order to prevent FDA ...

Novartis has over 3,000 employees working at its campus in East Hanover, and 12,000 employees nationwide, said Novartis spokesperson Michael Meo. The 427 layoffs will go into effect between June 13 ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.

For decades, the United States has led the world in pharmaceutical innovation – developing drugs that combat cancer, heart ...

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic ...